Latigo reported Q2 2026 financial results and business updates, including positive onzotrigine (LTG-001) results published in NEJM, an expanded leadership team and an upsized IPO that raised $397.4M in gross proceeds.
Read more: https://t.co/L9NfM4crhA
#Nav1.8 #NonOpioid $LTGO
Latigo CMO Neil Singla, M.D., will present “Cold Pressor as a Pharmacodynamic Biomarker for Nav1.8 Development” at the 20th Annual Pain Therapeutics Summit, Sept. 28–29 in San Francisco.
Learn more: https://t.co/lPxoKKHguv
#Nav1.8 #NonOpioid#PainResearch $LTGO